Compare LIN & TMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LIN | TMO |
|---|---|---|
| Founded | 1879 | 1956 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Industrial Machinery/Components |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 217.0B | 216.4B |
| IPO Year | N/A | N/A |
| Metric | LIN | TMO |
|---|---|---|
| Price | $409.43 | $589.84 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 17 |
| Target Price | $504.40 | ★ $611.19 |
| AVG Volume (30 Days) | ★ 2.9M | 1.6M |
| Earning Date | 10-31-2025 | 10-22-2025 |
| Dividend Yield | ★ 1.46% | 0.29% |
| EPS Growth | ★ 13.37 | 8.54 |
| EPS | 14.94 | ★ 17.32 |
| Revenue | $33,504,000,000.00 | ★ $43,736,000,000.00 |
| Revenue This Year | $3.68 | $4.28 |
| Revenue Next Year | $5.54 | $5.00 |
| P/E Ratio | ★ $27.46 | $34.12 |
| Revenue Growth | 1.45 | ★ 3.22 |
| 52 Week Low | $406.09 | $385.46 |
| 52 Week High | $486.38 | $610.97 |
| Indicator | LIN | TMO |
|---|---|---|
| Relative Strength Index (RSI) | 31.75 | 62.79 |
| Support Level | $406.09 | $556.46 |
| Resistance Level | $412.87 | $602.32 |
| Average True Range (ATR) | 6.44 | 13.45 |
| MACD | 0.30 | -0.41 |
| Stochastic Oscillator | 13.11 | 72.79 |
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $33 billion in revenue in 2024.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).